Skip to main content

Table 2 Adverse event frequency and severity (maximum National Cancer Institute Common Toxicity Criteria [NCI CTC] grade per category)

From: Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study

Adverse event/ organ system Patients per NCI CTC grade [n (%)]
grade 1 grade 2 grade 3 grade 4
Hematological     
 White blood cells 33 (31) 22 (20) 9 (8) 6 (6)
 Granulocytes 27 (26) 16 (15) 5 (5) 3 (3)
 Platelets 16 (15) 2 (2) 3 (3) 1 (1)
 Hemoglobin 43 (40) 40 (37) 3 (3) 3 (3)
 Fever 20 (19) 8 (7)   
Non-hematological     
 Hair loss 23 (21) 79 (73)   
 Nausea 53 (49) 15 (14)   
 Vomiting 32 (30) 10 (9)   
 Diarrhea 21 (19) 8 (7)   1 (1)
 Constipation 18 (17) 1 (1)   
 Neurology/Motor 19 (18) 6 (6) 4 (4)  
 Neurology/Sensory 28 (26) 16 (15) 5 (5)  
 Arthralgia 27 (25) 9 (8) 2 (2)  
 Myalgia 20 (19) 8 (7) 3 (3)  
 Lung function 11 (10) 8 (7) 2 (2) 3 (3)
 Pain 21 (19) 28 (26) 8 (7)